The NYSE Welcomes vVARDIS as a Publicly Listed Company

• vVARDIS (NYSE: VVVV) offers a drill-free, needle-free treatment for early tooth decay. • Curodont Repair Fluoride Plus uses peptide technology to remineralize enamel, treating 2.5M+ teeth. • Product is available in over 20% of U.S. dental practices; founders spent 25 years developing it. vVARDIS (NYSE: VVVV), a Swiss dental technology company co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, is targeting tooth decay—the world's most common non-communicable disease—with a drill-free, needle-free treatment. Tooth decay affects 2.5 billion people globally, with nearly 90% of U.S. adults having experienced it; dental anxiety, reported by 73% of U.S. adults, keeps 21% away from dentists entirely. The company's flagship product, Curodont® Repair Fluoride Plus, uses proprietary peptide technology to repair early-stage decay by supporting natural enamel remineralization, avoiding the need for drilling or fillings. Developed over 25 years, it has already been used to treat more than 2.5 million teeth and is now available in over 20% of U.S. dental practices. vVARDIS recently celebrated its IPO on the NYSE.